What are the risks and adverse effects of oral medroxyprogesterone acetate (Provera) 5–10 mg daily for 10–14 days each month in a 36‑year‑old woman?

Risks of Provera (Medroxyprogesterone Acetate)

Provera (medroxyprogesterone acetate) carries risks including thromboembolism, cardiovascular events, breast cancer concerns with prolonged use, and common side effects like mood changes, bloating, and irregular bleeding, though when used cyclically for 10-14 days monthly for endometrial protection, it remains a standard-of-care progestogen with an acceptable safety profile for most women.

Serious Risks Requiring Immediate Medical Attention

Thromboembolic Events

• Blood clots (thrombophlebitis, deep vein thrombosis, pulmonary embolism) 1
• Stroke and heart attack are absolute contraindications to starting Provera 1
• Risk appears lower than with combined estrogen-progestin contraceptives, but caution is warranted 2

Warning signs requiring immediate evaluation:

• Severe chest or leg pain with or without shortness of breath
• Sudden severe headaches
• Changes in vision or speech
• Weakness and fatigue 1

Cardiovascular Concerns

• Women with pre-existing cardiovascular disease should not use Provera 1
• Monitor lipid profiles and cardiovascular risk factors regularly 3
• Risk increases with tobacco use, hypertension, high cholesterol, diabetes, or obesity 1

Cancer-Related Risks

Breast cancer: Recent evidence suggests continuous progestogen exposure may increase breast cancer risk, which is why continuous daily regimens are not recommended 4. However, cyclic use (10-14 days monthly) appears safer 3, 4. The evidence remains mixed, with some studies showing increased risk and others showing no significant association 5, 6, 7.

Endometrial protection: Paradoxically, Provera reduces endometrial cancer risk when used appropriately with estrogen in women with an intact uterus 1.

Meningioma: A 2025 study found depot medroxyprogesterone acetate (injectable form) increased meningioma risk with prolonged use (>4 years) or when started after age 31, though the number needed to harm was high (1,152 patients) 8. Oral MPA showed a smaller increased risk (RR 1.18) with number needed to harm of 3,020 8.

Common Side Effects

Premenstrual-Like Symptoms

The most frequent complaints include 3, 1:

• Mood swings, depression, nervousness, irritability
• Bloating and fluid retention
• Sleep disturbances (insomnia or somnolence)
• Fatigue
• Headaches and dizziness

Important caveat: A 1994 placebo-controlled study found that medroxyprogesterone alone did not cause adverse symptoms in postmenopausal women, suggesting side effects may be related to the estrogen-progestin combination rather than MPA itself 9.

Bleeding Irregularities

• Breakthrough bleeding and spotting 1
• Changes in menstrual flow (increase or decrease)
• Amenorrhea (absence of periods) 1

Any unexpected vaginal bleeding requires endometrial evaluation with ultrasonography and biopsy 3.

Other Common Effects

• Breast tenderness or pain 1
• Weight changes (increase or decrease) 1
• Nausea and abdominal discomfort 1
• Acne, hair loss, or increased hair growth 1

Metabolic and Hormonal Effects

• Lipid alterations: MPA can affect cholesterol levels, though effects vary 3
• Glucose tolerance: May decrease glucose tolerance; monitor diabetic patients closely 1
• Blood pressure: Can cause fluid retention and affect blood pressure 3
• Thyroid function: May alter thyroid hormone levels 1

Absolute Contraindications

Do not use Provera if you have: 1

• Unusual vaginal bleeding (unexplained)
• Current or history of breast cancer
• Active or history of blood clots
• Stroke or heart attack history
• Active liver disease
• Known or suspected pregnancy
• Allergy to medroxyprogesterone acetate

Risk Mitigation Strategies

Dosing and Duration

• Use the lowest effective dose (typically 5-10 mg daily for 10-14 days monthly) 3, 4, 1
• Avoid continuous daily regimens due to breast cancer concerns 4
• Consider long-cycle therapy (14 days every 3 months) to reduce progestogen exposure, though efficacy is less established 4

Monitoring Requirements

• Regular discussions every 3-6 months about continued need 1
• Annual pelvic exam, breast exam, and mammogram 1
• More frequent breast surveillance if family history of breast cancer or prior abnormal findings 1
• Monitor lipid profiles and cardiovascular risk factors 3
• Low threshold for endometrial sampling with any abnormal bleeding 3

Alternative Considerations

If side effects are intolerable, consider switching to 3:

• Micronized progesterone (200 mg for 12-14 days monthly): Associated with fewer side effects, better cardiovascular profile, and improved sleep 10, 11, 12
• Transdermal progestogen patches (if available)
• Other synthetic progestins (norethindrone acetate, dydrogesterone)

Special Populations

Perimenopausal women (age 36): At this age, cyclic MPA 5-10 mg for 10-14 days monthly is appropriate for endometrial protection when using estrogen, or for managing irregular cycles 3. The cardiovascular and thrombotic risks are lower in younger women without other risk factors 2.

Before surgery or prolonged bed rest: Discuss stopping Provera temporarily due to increased thrombotic risk 1.

Breastfeeding: MPA passes into breast milk; discuss risks/benefits 1.

Clinical Bottom Line

For a 36-year-old woman using Provera 5-10 mg daily for 10-14 days monthly, the primary concerns are mood-related side effects and bleeding irregularities, which are common but manageable. Serious risks (thromboembolism, cardiovascular events) are relatively rare in this age group without additional risk factors. The regimen provides essential endometrial protection when using estrogen and represents standard care 3, 4. However, continuous daily use should be avoided due to breast cancer concerns 4, and micronized progesterone may offer a superior safety profile if side effects become problematic 10, 11, 12.